Currently out of the existing stock ratings of Katie Tryhane, 8 are a BUY (80%), 2 are a SELL (20%).

Katie Tryhane

Work Performance Price Targets & Ratings Chart

Analyst Katie Tryhane, carries an average stock price target met ratio of 57.14% that have a potential upside of 13.44% achieved within 63 days.

Katie Tryhane’s has documented 20 price targets and ratings displayed on 7 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on CRL, Charles River Laboratories at 24-Aug-2022.

Wall Street Analyst Katie Tryhane

Analyst best performing recommendations are on MRVI (MARAVAI LIFESCIENCES HOLDINGS ).
The best stock recommendation documented was for MRVI (MARAVAI LIFESCIENCES HOLDINGS ) at 8/11/2021. The price target of $54 was fulfilled within 1 day with a profit of $4 (8%) receiving and performance score of 80.

Average potential price target upside

CRL Charles River Laboratories DHR Danaher FLGT Fulgent Genetics IDXX IDEXX Laboratories MRVI Maravai Lifesciences Holdings  SYNH Syneos Health ZTS Zoetis

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold

$174

$-4.52 (-2.53%)

$155

2 days ago
(16-Oct-2025)

4/5 (80%)

$-4.52 (-2.53%)

60

Buy

$200

$21.48 (12.03%)

$180

16 days ago
(02-Oct-2025)

4/8 (50%)

$22.67 (12.78%)

86

Buy

$195

$16.48 (9.23%)

$165

17 days ago
(01-Oct-2025)

6/7 (85.71%)

$19.64 (11.20%)

54

Buy

$195

$16.48 (9.23%)

$203

1 months 10 days ago
(08-Sep-2025)

12/15 (80%)

$37.62 (23.90%)

94

Hold

$160

$-18.52 (-10.37%)

$165

2 months 12 days ago
(06-Aug-2025)

4/4 (100%)

$10.22 (6.82%)

17

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Katie Tryhane?

On 2018

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?